Breaking News

Close

Gilead Sciences Inc (GILD)

	Symbol	Exchange	Currency
	GILD	NASDAQ	USD	Real-time
	GILD	Mexico	MXN	Delayed
	GGILD	Milan	EUR	Real-time
	GILD	Xetra	EUR	Delayed
	GILD	Frankfurt	EUR	Delayed
	GILD	TradeGate	EUR	Delayed
	GILD	Buenos Aires	ARS	Delayed
	GILD	Vienna	EUR	Real-time
	GILD	Lima	USD	Delayed

Add to/Remove from a Portfolio Add to Watchlist

1,290.00 0.00 0.00%

18/09 - Closed. Currency in MXN ( Disclaimer )

Volume: 0
Bid/Ask: 0.00 / 0.00
Day's Range: 1,290.00 - 1,290.00

Type: Equity

Market: Mexico

ISIN: US3755581036

S/N: 375558103

General
Chart
- Streaming Chart
- Interactive Chart
News & Analysis
- News
- Analysis & Comment
Financials
Technical
Forum

NASDAQ:GILD Financials

See below for an overview of the Gilead financial reports. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track the NASDAQ:GILD financials over time.

Gilead Sciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 6,599 million compared to USD 6,260 million a year ago. Net income was USD 1,045 million compared to USD 1,144 million a year ago. Basic earnings per share from continuing operations was USD 0.84 compared to USD 0.91 a year ago. Diluted earnings per share from continuing operations was USD 0.83 compared to USD 0.91 a year ago.For the six months, revenue was USD 12,951 million compared to USD 12,850 million a year ago. Net income was USD 2,055 million compared to USD 1,163 million a year ago. Basic earnings per share from continuing operations was USD 1.65 compared to USD 0.93 a year ago. Diluted earnings per share from continuing operations was USD 1.63 compared to USD 0.92 a year ago.

Annual Quarterly

InvestingPro

Advanced Financial Summary

TTM = Trailing Twelve Months

MRQ = Most Recent Quarter

GILD Income Statement

Gross margin TTM 79.42%

Operating margin TTM 35.75%

Net Profit margin TTM 20.03%

Return on Investment TTM 15.62%

Total Revenue Net Income

Period Ending:	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022
Total Revenue	6599	6352	7389	7042
Gross Profit	5157	4951	5993	5647
Operating Income	1932	2182	2406	3315
Net Income	1045	1010	1640	1789

GILD Balance Sheet

Quick Ratio MRQ 0.81

Current Ratio MRQ 1.02

LT Debt to Equity MRQ 100.24%

Total Debt to Equity MRQ 119.32%

Total Assets Total Liabilities

Period Ending:	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022
Total Assets	62337	61876	63171	62557
Total Liabilities	41243	40937	41962	41500
Total Equity	21094	20939	21209	21057

GILD Cash Flow Statement

Cash Flow/Share TTM 7.63

Revenue/Share TTM 21.95

Operating Cash Flow 16.74%

Cash Net Change in Cash

Period Ending:	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022
Period Length:	0 Months	0 Months	0 Months	0 Months
Cash From Operating Activities	2337	1744	2567	2863
Cash From Investing Activities	-483	-826	-375	-713
Cash From Financing Activities	-1101	-1406	-1554	-2118
Net Change in Cash	768	-476	713	-40

* In Millions of USD (except for per share items)

InvestingPro

Go to Dashboard InvestingPro

InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:

Enrich the conversation
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically.
Use standard writing style. Include punctuation and upper and lower cases.
NOTE: Spam and/or promotional messages and links within a comment will be removed
Avoid profanity, slander or personal attacks directed at an author or another user.
Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I have read and understood Investing.com UK's comment guidelines and agree to the terms described.

GILD Comments

Write your thoughts about Gilead Sciences Inc

Are you sure you want to delete this chart?

Post also to:

Replace the attached chart with a new chart ?

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

Oc Masai Apr 27, 2021 7:54

Follow this post

Unfollow this post

Saved. See Saved Items.

This comment has already been saved in your Saved Items

Good job GILD. bullish move forward

0 0

Ashraf Elgendy Mar 07, 2021 13:03

Follow this post

Unfollow this post

Saved. See Saved Items.

This comment has already been saved in your Saved Items

Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...

2 1

RM RM Mar 01, 2021 21:53

Follow this post

Unfollow this post

Saved. See Saved Items.

This comment has already been saved in your Saved Items

Up Again

1 0

Ken Laing Oct 23, 2020 18:43

Follow this post

Unfollow this post

Saved. See Saved Items.

This comment has already been saved in your Saved Items

Time to load up before the big rise coming next week

3 3

Iggy Maldon Jul 30, 2020 20:22

Follow this post

Unfollow this post

Saved. See Saved Items.

This comment has already been saved in your Saved Items

Classic pump n’ dump. What a shambles

5 1

RM RM May 28, 2020 22:24

Follow this post

Unfollow this post

Saved. See Saved Items.

This comment has already been saved in your Saved Items

Will reach above 95

10 5

Chili Daug May 28, 2020 22:24

Follow this post

Unfollow this post

Saved. See Saved Items.

This comment has already been saved in your Saved Items

when? hahah

0 0

SAGAR AGARWAL May 15, 2020 14:52

Follow this post

Unfollow this post

Saved. See Saved Items.

This comment has already been saved in your Saved Items

Good time to accumulate.

4 1

Khizer Malik May 14, 2020 11:04

Follow this post

Unfollow this post

Saved. See Saved Items.

This comment has already been saved in your Saved Items

Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr

8 2

Willy Chin Apr 23, 2020 18:14

Follow this post

Unfollow this post

Saved. See Saved Items.

This comment has already been saved in your Saved Items

High chance to be trading above 90, good long stock

9 4

Viktor Veselý Apr 12, 2020 7:48

Follow this post

Unfollow this post

Saved. See Saved Items.

This comment has already been saved in your Saved Items

By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.

4 3

<div id="comment">
				<div class="comment js-comment" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="204313794">
    <div class="mainComment js-content">
       <div class="commentInnerWrapper">
        <a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody">
                					<span class="commentUsername">
                    	<a href="{userLink}" class="js-user-link js-user-name">{username}</a>
					</span>
                                <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
                <div class="commentDropDown js-commentDropDownWrapper " data-user-id="204313794" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

<div class="js-option addRow follow">
            <div class="js-follow-post-button" data-reg_ep="follow comment">
                <span class="alertfollowIcon middle"></span>Follow this post            </div>
            <div class="js-unfollow-post-button displayNoneImp">
                <span class="alertUnfollowIcon middle"></span>Unfollow this post            </div>
        </div>

<div class="addRow js-option save"  data-reg_ep="save comment">
		<a href="javascript:void(0);" class="js-save-item-btn" data-item-type="comments" data-item-id="{commentID}">
			<i class="saveItemBigIcon middle"></i>
			Save		</a>
	</div>
	<div class="addRow saveItemsConfirmation noHover displayNone js-saveItemResult">
		
<div class="content js-saveItemSuccess displayNone">
	<span class="mediumGreenSuccessIcon"></span><span>Saved. See <a href="/members-admin/saved-items" target="_blank">Saved Items</a>.</span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
<div class="content js-saveItemAlreadySaved saveItemAlreadySaved displayNoneImp">
	<span>This comment has already been saved in your <a href="/members-admin/saved-items" target="_blank">Saved Items</a></span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
	</div>

<div class="addRow js-option blockUser js-block-option" data-comment-id="{commentID}"  data-user-id="204313794" data-reg_ep="block user comments">
			<a href="javascript:void(0);">
				<span class="blockIcon middle"></span>Block User			</a>
		</div>
				<div class="addRow shareButtons js-sharePopup displayNone">
			<div class="js-shareComment"><span class="js-shareCommentSpan"></span></div>
		</div>
	</div>
</div>
                 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div>             </div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="commentBigChart js-comment-chart" onclick="openViewChartPopup('{commentID}')">
					<img src="https://d51-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="204313794">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

<div class="reportComment js-flag float_lang_base_2">
                            <a href="javascript:void(0);" id="commentFlag_{commentID}">
                                <span class="reportCommentIcon middle"></span><span class="inlineblock middle">Report</span>
                            </a>
                        </div>
                    				</div>
					</div>
	   </div>
	</div>
	</div>			</div>
			<div id="reply">
				
    <div class="commentReply js-comment js-comment-reply" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="200889478">
		<div class="commentInnerWrapper"><a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody js-content">
            				<span class="commentUsername">
					<a href="{userLink}" class="commentUsername js-user-link js-user-name" onMouseOver="">{username}</a>
				</span>
                        <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
			 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div> 			<div class="commentDropDown js-commentDropDownWrapper " data-user-id="200889478" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

<div class="js-option addRow follow">
            <div class="js-follow-post-button" data-reg_ep="follow comment">
                <span class="alertfollowIcon middle"></span>Follow this post            </div>
            <div class="js-unfollow-post-button displayNoneImp">
                <span class="alertUnfollowIcon middle"></span>Unfollow this post            </div>
        </div>

<div class="addRow js-option save"  data-reg_ep="save comment">
		<a href="javascript:void(0);" class="js-save-item-btn" data-item-type="comments" data-item-id="{commentID}">
			<i class="saveItemBigIcon middle"></i>
			Save		</a>
	</div>
	<div class="addRow saveItemsConfirmation noHover displayNone js-saveItemResult">
		
<div class="content js-saveItemSuccess displayNone">
	<span class="mediumGreenSuccessIcon"></span><span>Saved. See <a href="/members-admin/saved-items" target="_blank">Saved Items</a>.</span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
<div class="content js-saveItemAlreadySaved saveItemAlreadySaved displayNoneImp">
	<span>This comment has already been saved in your <a href="/members-admin/saved-items" target="_blank">Saved Items</a></span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
	</div>

<div class="addRow js-option blockUser js-block-option" data-comment-id="{commentID}"  data-user-id="200889478" data-reg_ep="block user comments">
			<a href="javascript:void(0);">
				<span class="blockIcon middle"></span>Block User			</a>
		</div>
				<div class="addRow shareButtons js-sharePopup displayNone">
			<div class="js-shareComment"><span class="js-shareCommentSpan"></span></div>
		</div>
	</div>
</div>

</div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="replyBigChart displayNone js-comment-chart">
					<img src="https://d51-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
				<span id="commentSmallChart{commentID}" class="commentSmallChart pointer js-comment-chart" onclick="openViewChartPopup('{commentID}')">
                    <img src="https://d51-invdn-com.investing.com/comments_images/{commentImageSmall}" width="116" height="52" alt="{commentAlt}">
                    <span class="chartMagnifyOverlay displayNone"></span>
                    <span class="searchGlassIcon chartMagnify displayNone"></span>
                </span>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="200889478">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

<div class="reportComment js-flag float_lang_base_2">
                            <a href="javascript:void(0);" id="commentFlag_{commentID}">
                                <span class="reportCommentIcon middle"></span><span class="inlineblock middle">Report</span>
                            </a>
                        </div>
                    				</div>
					</div>
		</div>
    </div>
			</div>
			<div id="show-more-comments">
				<a class="showMoreComments block">
					<span class="arial_12 showArrowafter">Show more comments (<span class="js-amount"></span>)</span>
				</a>
			</div>
			<div id="show-more-replies">
				<a class="showMoreReplies block">
					<span class="arial_12 showArrowafter">Show more replies (<span class="js-amount"></span>)</span>
				</a>
			</div>

Are you sure you want to delete this chart?

Replace the attached chart with a new chart ?

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

I feel that this comment is:

Spam

Offensive

Thank You!

Your report has been sent to our moderators for review

More Categories

1D1W1M6M1Y5YMax

	FTSE 100	7,593.22	-32.50	-0.43%
	DAX	15,217.45	-38.42	-0.25%
	Euro Stoxx 50	4,131.65	+2.47	+0.06%
	S&P 500	4,274.51	+0.98	+0.02%
	Nikkei 225	31,851.00	-479.50	-1.48%
	Dow Jones	33,550.27	-68.61	-0.20%
	FTSE 100 Futures	7,644.5	+9.3	+0.12%

	Brent Oil	94.94	+0.58	+0.61%
	Crude Oil WTI	94.47	+0.79	+0.84%
	Gold	1,891.65	+0.75	+0.04%
	Silver	22.698	-0.026	-0.11%
	Copper	3.6422	-0.0028	-0.08%
	London Cocoa	2,966.00	0.00	0.00%
	London Wheat	192.00	-0.75	-0.39%

	U.K. 10Y	4.3915	+0.0315	+0.72%
	U.K. 5Y	4.5030	+0.0360	+0.81%
	U.K. 2Y	4.9075	+0.0325	+0.67%
	Germany 10Y	2.8465	+0.0145	+0.51%
	U.S. 10Y	4.602	-0.029	-0.63%
	U.S. 5Y	4.678	-0.028	-0.59%
	U.S. 2Y	5.121	-0.020	-0.39%

	Lloyds Banking	44.57	-0.35	-0.79%
	Vodafone Group PLC	79.32	-1.39	-1.72%
	Barclays	158.12	-1.56	-0.98%
	BT Group	117.30	-0.35	-0.30%
	HSBC	639.90	+0.70	+0.11%
	BHP Group Ltd	2,298.00	+14.50	+0.64%
	Exxon Mobil	120.20	+3.79	+3.26%

Recent Quotes

	Name	Price	Chg.	Chg. %
	GILD	1,290.00	0.00	0.00%

	Name	Last	Chg. %	Vol.
	BP	538.50	+1.43%	24.03M
	HSBC	639.90	+0.11%	15.04M
	Shell	2,629.5	+1.15%	5.32M
	British American Tobacco	2,624.5	-0.83%	4.54M
	CRH	4,494.0	-2.77%	3.97M
	Flutter Entertainment	13,645.0	-0.07%	1.08M
	AstraZeneca	11,118.0	-0.41%	1.01M

	Name	Last	Chg. %	Vol.
	Frontline	198.90	+75.55%	2.06K
	Spiritus Mundi	5.50	+37.50%	224.75K
	MGC Pharma	0.07	+36.36%	32.21M
	Saipem	1.46	+34.38%	5.13M
	Amigo	0.45	+28.57%	18.83M
	Saietta Group	40.00	+25.00%	303.65K
	Dukemount	0.14	+22.73%	33.07M

	Name	Last	Chg. %	Vol.
	BioGaia B	98.65	-80.86%	0.51K
	H Lundbeck B	37.44	-78.45%	26.66K
	Atlas Copco B	123.70	-67.26%	52.93K
	Tomra Systems	123.55	-64.47%	30.56K
	Inland ZDP Prf	48.00	-49.47%	8.45K
	Electrolux B	109.85	-45.61%	295.38K
	Itsarm	0.78	-35.29%	14.46M